On Friday, the World Health Organization (WHO) announced its prequalification approval of Artemether-lumefantrine, the first malaria treatment specifically designed for newborns and infants. This significant development aims to reduce the risks associated with adult formulations, which have been used for infants until now, leading to potential dosage errors and side effects. WHO Director-General Tedros Adhanom Ghebreyesus emphasized the importance of this approval, stating that malaria has historically devastated communities, particularly affecting children. In 2024, the WHO reported approximately 282 million malaria cases and 610,000 deaths globally, with 95% of these occurring in Africa, where children under five account for three-quarters of the fatalities. The new treatment will help close a long-standing gap in care for around 30 million newborns born annually in malaria-endemic areas. However, the WHO also noted that challenges such as drug resistance and reduced foreign aid are hindering progress in combating malaria.